Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme’s Lemtrada Approved by the FDA
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Biogen Idec's long-acting beta interferon moves ahead in MS
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
The challenge of comorbidity in clinical trials for multiple sclerosis.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Spin-offs: Meet the structure specialists
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Food and Drug Administration drug insert for Campath (alemtuzumab)
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.

Pages